

CPH Istanbul 2016

The leading pharma event in MENA and Turkey, CPH Istanbul, returns March 8th-10th 2017 for its fourth consecutive year. Following record breaking exhibitor and attendee numbers in 2016, CPH Istanbul 2017 stands to be a unique forum for representatives from both the local and international pharma industry.

With the show's growing success, co-located with ICSE, P-MED and Innopack, CPH Istanbul will now take place in a new, larger venue at

the Istanbul Expo Center in 2017. As a bridge between Europe and Asia, Istanbul continues to provide an unrivalled meeting point for pharma professionals to build new partnerships and gather market insight.

With a rapidly evolving pharma economy, Turkey rises no doubt as a market with huge potential and the ideal location for such an exhibition. Having already cemented itself as a pharmaceutical hub, Turkey's pharma market already hosts nearly 90 pro-

duction facilities, 20,000 employees and direct access to the markets of the Middle East and North Africa. Set to experience the fastest growth rate in the OECD – averaging 6.7% per year from 2011-2018 – Turkey has positioned itself to emerge as a top ten global healthcare economy by 2023.

CPH Istanbul 2017 will continue to serve as an invaluable opportunity for pharma professionals. For more information, visit: www.cphi.com/istanbul or contact: Karen.maguire@ubm.com.

Chemistry for a Bright Future.



Learn more at Booth 1F40



APELOA 普洛
A member of the Hengdian Group, a public company

T: +86-571-8763 5800
F: +86-571-8799 0222
E: info@hengdian-group.com

www.hengdian-group.com

Hengdian Group, established in 1975, is one of the largest privately owned enterprises in China. Our main focus is creating a healthy life and future. Hengdian provides CMO services with integrated EHS management systems and products from 3 cGMP and FDA approved manufacturing sites.

- Scientific Services and Global Resources
- API and intermediates research, production and distribution
- Fluorination Experts
- Asymmetric Synthesis, Cryogenic Reactions and Heterocycles
- Trusted Global Sourcing and Dependable Sales

Pierre Fabre CD

Pierre Fabre Reorganizes Into A CDMO Model

Pierre Fabre recently reorganised its Contract Manufacturing Organisation (CMO) into a Development & Manufacturing (CDMO) model to reinforce competitiveness in three specialized domains:

- Sterile injectable drugs (biologics and antibodies)
 - Oral products, in particular pharmaceutical lozenges
 - Chemistry of active ingredients
- Significant investments have been dedicated to those three divisions to extend current production capacities. The Pierre FABRE CDMO team has division-dedicated business developers, technical experts and project managers to work on your projects. The company's global strategic plan, "Trajectoire 2018", has set solid foundations for future manufacturing capacities to compete strongly within the worldwide CDMO arena. Company focus during the CPHI show will be in biotechnology products, particularly in the fill & finish of ADC and monoclonal antibodies, recombinant proteins, both for NBE and biosimilars. Visit Stand 3N50 to discuss your requirements with experts.

SA KitoZyme Stand no 7D63SSP

SA KitoZyme Launches Four New Products

SA KitoZyme, whose expertise falls into cardiovascular and digestive health and weight management, launches four new products at FDF. Gastrap chewable tablets ease symptomatic gas-related GI complaints. TransiRelax is a food supplement to support gastrointestinal health, improving the body's ability to adapt to stress. TransiBota treats moderate constipation by regulating transit, whilst FiberSim reduces calorie intake whilst restoring gut microflora. Beginning as a spin-off of the University of Liège, Belgium, KitoZyme is a weight management market leader in Germany, France and Belgium and globally recognised for its patented biopolymer, non-animal chitosan production and R&D.

Piramal anticipates bigger role of CMOs in Biological Formulations



Unlike most of the drugs which are manufactured in an ordered process through chemical synthesis, biologics involve large and complex molecules majority produced using recombinant DNA technology. Therefore, for biologics, "the product is the process." Because the finished product cannot be fully characterized in the laboratory, manufacturers must ensure product consistency, quality, and purity by ensuring that the manufacturing process remains substantially the same over time.

Not only are biologics more difficult to produce, with more complex supply chains, but they are also significantly more expensive to develop and manufacture. Because of that demonstrated size as well as the complex physicochemical interactions between a protein and its environment, biologic-based therapeutics must be handled differently from their small molecule counterparts.

Rapid Shift in Market Dynamics—Drug development pipelines have filled with biologics, and a handful of monoclonal antibody (mAb) products have become some of the best-selling drugs around the world. The biologics market is growing 10–15% year over year and accounts for 20% of pharmaceutical sales and about 50% of the overall R&D spend in value terms is on Biological Products. More than 75% of companies in the Biological Space outsource the Fill/Finish Operations to CMOs but, the depth of outsourcing is only at about 36% of all Fill/Finish Operations, up from 34% in 2015.

Future Trends—The fill/finish industry will invest heavily on ramp-up of technologies and capabilities. The CMOs are expected to invest heavily on their capabilities and capacities related to fill/finish various types of Biological Products.

For more information visit us at www.piramal.com.

CPH Russia 2016

As the Russian government continues to boost the pharma industry with its ambitious 2020 plan, what better time to benefit from the opportunities the Russian pharma market has to offer? The Russian government is investing money to attract foreign partnerships by fast-track approval processes, tax incentives and global promotion of Russian pharmaceutical manufacturing and research & development. The country is also experiencing an increasing finished dosage manufacturing capacity.

For newcomers in the Russian market, it is essential to network and create business partnerships with domestic players to gain foothold of the market. Participating in CPHI Russia & IPHEB means that you will be participating in the most all-round pharmaceutical event, the region has to offer. The event offers complimentary Forum discussions and seminars, with some of the leading pharma experts, so that you can gain in-depth knowledge about the regions market. You will also be able to network

with top-level executives via the highly acclaimed Matchmaking programme – free for all attendees of the show. CPHI Russia & IPHEB is collocated with P-MED, to showcase the latest pharma machinery, equipment and technology, and Innopack to bring the latest innovations in packaging and drug delivery. The event brings companies in the field of ingredients, finished dosage, packaging, technology, and machinery. Learn more about the event via www.cphi.com/russia.

galenIQ™ – the bulk filler-binder.

Great choice. Great taste.



- galenIQ™ is pharma-grade Isomalt (Ph. Eur., USP-NF, BP, JP) that makes medicine taste pleasant.
- The filler-binder with sweet sugar-like taste.
- Due to its multifunctionality your best choice excipient to be used for a broad variety of dosage forms.

Come and visit us at
BOOTH #4L75

Our team of experts is available for your product development with galenIQ™. Please contact us: info@galenIQ.com - www.galenIQ.com

galenIQ™
a brand of benes